Lantheus (NASDAQ:LNTH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday. The brokerage presently has a $20.00 target price on the medical equipment provider’s stock. Zacks Investment Research‘s price target indicates a potential upside of 7.87% from the company’s previous close.
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
LNTH has been the subject of a number of other research reports. ValuEngine lowered Lantheus from a “hold” rating to a “sell” rating in a research note on Wednesday, October 31st. BidaskClub raised Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, November 22nd. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $20.33.
NASDAQ:LNTH opened at $18.54 on Thursday. The company has a market cap of $709.77 million, a PE ratio of 18.54, a P/E/G ratio of 3.56 and a beta of 1.47. Lantheus has a fifty-two week low of $12.59 and a fifty-two week high of $21.45. The company has a quick ratio of 2.87, a current ratio of 3.50 and a debt-to-equity ratio of 4.76.
In related news, CEO Mary Anne Heino sold 9,564 shares of the firm’s stock in a transaction on Wednesday, January 30th. The stock was sold at an average price of $16.47, for a total value of $157,519.08. Following the completion of the sale, the chief executive officer now owns 630,782 shares of the company’s stock, valued at $10,388,979.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Cesare Orlandi sold 3,060 shares of the firm’s stock in a transaction on Thursday, January 31st. The stock was sold at an average price of $16.56, for a total value of $50,673.60. Following the completion of the sale, the insider now directly owns 77,746 shares of the company’s stock, valued at approximately $1,287,473.76. The disclosure for this sale can be found here. Insiders sold 23,736 shares of company stock valued at $408,523 in the last ninety days. 1.20% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the stock. PNC Financial Services Group Inc. lifted its stake in Lantheus by 51.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 575 shares during the period. Financial Gravity Companies Inc. purchased a new stake in Lantheus in the fourth quarter worth $45,000. Advisor Group Inc. lifted its stake in Lantheus by 1,837.2% in the fourth quarter. Advisor Group Inc. now owns 4,378 shares of the medical equipment provider’s stock worth $69,000 after acquiring an additional 4,152 shares during the period. Gotham Asset Management LLC purchased a new stake in Lantheus in the fourth quarter worth $165,000. Finally, Municipal Employees Retirement System of Michigan purchased a new stake in Lantheus in the fourth quarter worth $171,000. 96.95% of the stock is owned by institutional investors.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
See Also: Trading Options- What is a Strangle?
Get a free copy of the Zacks research report on Lantheus (LNTH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.